Candel Therapeutics, Inc.
Candel Therapeutics, Inc. (Nasdaq: CADL) is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies intended to stimulate local and systemic anti-tumor immune responses. Its candidates are administered directly into tumors and are designed to prompt tumor-cell destruction and immune… From the company’s description.
In fiscal 2025, Candel Therapeutics, Inc. reported a net loss of $38.18M. Operations used $38.31M in cash.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Candel Therapeutics, Inc. does
In the company’s own words
Candel Therapeutics, Inc. (Nasdaq: CADL) is a clinical-stage biopharmaceutical company developing off-the-shelf viral immunotherapies intended to stimulate local and systemic anti-tumor immune responses. Its candidates are administered directly into tumors and are designed to prompt tumor-cell destruction and immune activity against injected and distant tumors. The company’s two clinical platforms use genetically modified adenoviruses and herpes simplex viruses (HSV). Its lead candidate, aglatimagene besadenovec, is an adenovirus therapy studied with valacyclovir and other treatments across prostate cancer, non-small cell lung cancer and pancreatic cancer; linoserpaturev, an HSV-based candidate, is being studied for recurrent high-grade glioma. The enLIGHTEN Discovery Platform supports the design of additional HSV-based candidates, including preclinical programs for solid tumors. Candel conducts research and development across these programs and relies on third-party manufacturers for commercial-scale production. The company was incorporated as Advantagene in 2003, licensed Periphagen assets in 2019 and linoserpaturev in 2020, and adopted the Candel Therapeutics name in December 2020. Its website is https://www.candeltx.com/.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- NEEDHAM, MA
- Fiscal year end
- December
- CIK
- 1841387
- SIC
- 2836
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Candel Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Candel Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Candel Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Candel Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Candel Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”